July 9, 2026 · Form 4 insider transaction
Valentine Keith bought 24,826 shares of Regentis Biomaterials Ltd. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026.; This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029.